Black Friday saleUp to 70% OFF
THYROCARE TECHNOLOGIES LIMITEDTHYROCARE TECHNOLOGIES LIMITEDTHYROCARE TECHNOLOGIES LIMITED

THYROCARE TECHNOLOGIES LIMITED

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

THYROCARE chart


Full chart

THYROCARE upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪53.95 B‬ INR
Dividend yield (indicated)
1.77%
Price to earnings Ratio (TTM)
65.20
Basic EPS (TTM)
15.85 INR
Net income (FY)
‪707.60 M‬ INR
Revenue (FY)
‪5.72 B‬ INR
Shares float
‪15.25 M‬
Beta (1Y)
0.41

Employees


Employees (FY)
‪1.69 K‬
Change (1Y)
+48 +2.92%
Revenue / Employee (1Y)
‪40.50 K‬ INR
Net income / Employee (1Y)
‪5.01 K‬ INR

About THYROCARE TECH LTD


Sector
Health Services
Industry
Medical/Nursing Services
CEO
Rahul Franklin Guha
Website
thyrocare.com
Headquarters
Navi Mumbai
Founded
1996
ISIN
INE594H01019
FIGI
BBG00BT3H614
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. It operates through the following segments: Diagnostic Testing Services, Imaging Services and Others. The Imaging Services segment represents PET-CT scan and sale of radio pharmaceuticals used in imaging services. The Others segment represents trading and other related business activities. The company was founded by A. Velumani in 1996 and is headquartered in Navi Mumbai, India.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

THYROCARE news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of THYROCARE is 968.05 INR — it has decreased by −1.82% in the past 24 hours. Watch THYROCARE TECHNOLOGIES LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange THYROCARE TECHNOLOGIES LIMITED stocks are traded under the ticker THYROCARE.
THYROCARE stock has risen by 2.98% compared to the previous week, the month change is a 13.37% rise, over the last year THYROCARE TECHNOLOGIES LIMITED has showed a 74.66% increase.
We've gathered analysts' opinions on THYROCARE TECHNOLOGIES LIMITED future price: according to them, THYROCARE price has a max estimate of 1,040.00 INR and a min estimate of 975.00 INR. Watch THYROCARE chart and read a more detailed THYROCARE TECHNOLOGIES LIMITED stock forecast: see what analysts think of THYROCARE TECHNOLOGIES LIMITED and suggest that you do with its stocks.
THYROCARE reached its all-time high on Jun 25, 2021 with the price of 1,465.90 INR, and its all-time low was 406.65 INR and was reached on Jul 31, 2019. View more price dynamics on THYROCARE chart.
See other stocks reaching their highest and lowest prices.
THYROCARE stock is 4.89% volatile and has beta coefficient of 0.41. Track THYROCARE TECHNOLOGIES LIMITED stock price on the chart and check out the list of the most volatile stocks — is THYROCARE TECHNOLOGIES LIMITED there?
Today THYROCARE TECHNOLOGIES LIMITED has the market capitalization of ‪53.95 B‬, it has decreased by −1.28% over the last week.
Yes, you can track THYROCARE TECHNOLOGIES LIMITED financials in yearly and quarterly reports right on TradingView.
THYROCARE TECHNOLOGIES LIMITED is going to release the next earnings report on Jan 31, 2025. Keep track of upcoming events with our Earnings Calendar.
THYROCARE net income for the last quarter is ‪266.70 M‬ INR, while the quarter before that showed ‪241.70 M‬ INR of net income which accounts for 10.34% change. Track more THYROCARE TECHNOLOGIES LIMITED financial stats to get the full picture.
Yes, THYROCARE dividends are paid annually. The last dividend per share was 18.00 INR. As of today, Dividend Yield (TTM)% is 1.77%. Tracking THYROCARE TECHNOLOGIES LIMITED dividends might help you take more informed decisions.
THYROCARE TECHNOLOGIES LIMITED dividend yield was 3.04% in 2023, and payout ratio reached 134.66%. The year before the numbers were 4.19% and 147.70% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 28, 2024, the company has ‪1.69 K‬ employees. See our rating of the largest employees — is THYROCARE TECHNOLOGIES LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. THYROCARE TECHNOLOGIES LIMITED EBITDA is ‪1.56 B‬ INR, and current EBITDA margin is 24.98%. See more stats in THYROCARE TECHNOLOGIES LIMITED financial statements.
Like other stocks, THYROCARE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade THYROCARE TECHNOLOGIES LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So THYROCARE TECHNOLOGIES LIMITED technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating THYROCARE TECHNOLOGIES LIMITED stock shows the buy signal. See more of THYROCARE TECHNOLOGIES LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.